Funding
Nabriva Therapeutics of Vienna, which is developing a new class of antibiotics for serious infections caused by resistant pathogens, has announced the closing of a €15 million financing. This brings the total raised by the company since its formation in 2006 to €57.4 million.
Existing investors Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund all participated in this round.
David Chiswell, CEO of Nabriva Therapeutics, said the money extends Nabriva’s cash into 2011. “[It] will fund the development of our systemic pleuromutilin program up to and including the generation of Phase II efficacy data in the second half of 2010.”
Ralf Schmid, CFO of Nabriva, added, “We are delighted that our existing investors have shown such a solid commitment to Nabriva and its drug candidates.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
